GET DAILY SIGNALSWhy Is Milestone Pharmaceuticals (MIST) Stock Down -7.22% Today?
Key Takeaways
- Shares fell roughly 7.2% to about $0.65, extending a multi-month decline and undercutting the prior 52-week low of $0.69.
- Primary pressure: persistent doubts over the slow commercial launch of CARDAMYST (etripamil), which generated just $0.6 million in second-quarter product revenue against a $28.6 million net loss.
- Secondary drivers: a financing and dilution overhang, unusually heavy short interest (about 135% of the float), and a string of Wall Street price-target reductions.
- Broader context: micro-cap biotechnology remains out of favor, and MIST is down roughly 65% year-to-date.
- What traders are watching next: third-quarter results (expected around November 11), plus updates on payer coverage, prescription trends, and the AFib-RVR Phase 3 program.
- For more detail on this name, explore its Price Targets, Earnings, and Forecast pages.
- Discover the strongest-performing strategies in current market conditions through Trending AI Robots.
Opening Summary
Milestone Pharmaceuticals Inc. (MIST), a Montréal-based biopharmaceutical company developing cardiovascular medicines, saw its stock sink on Friday. The company's lead product is CARDAMYST (etripamil) nasal spray, an FDA-approved therapy for the acute treatment of paroxysmal supraventricular tachycardia (PSVT). Shares dropped about 7.2% to roughly $0.65, down from a prior-session close of $0.7027, and slid below the stock's previous 52-week low of $0.69. The decline reflected renewed selling in a heavily shorted name still struggling to convince investors that its first commercial product is gaining real traction.
Slow CARDAMYST Launch Weighs on Sentiment
The core issue pressuring the stock is the sluggish ramp of CARDAMYST. In its first full quarter of commercial sales, the company reported just $0.6 million in product revenue, a figure dwarfed by a $28.6 million net loss. While management has highlighted encouraging early signs—more than 600 independent prescribers and over 1,200 prescriptions in the second quarter, alongside commercial insurance coverage surpassing 50% of covered lives—revenue conversion has lagged investor expectations. That gap between prescription activity and actual top-line growth has kept the stock under sustained selling pressure.
Financing, Dilution, and Short-Selling Pressure
Beyond the launch itself, MIST carries a meaningful financing and dilution overhang. The share count has grown sharply over the past year, and the company holds outstanding warrants and convertible debt that could further increase the float. With shares trading well below $1, investors are also weighing Nasdaq minimum-bid and potential reverse-split considerations. Compounding the move, short interest remains exceptionally elevated at more than 100% of the float, leaving the name vulnerable to continued technical selling as it makes new lows.
Analyst Expectations Reset Lower
The downtrend has been reinforced by a steady trimming of Street expectations. Analysts have lowered price targets and average fair-value estimates, citing a more cautious view of CARDAMYST launch execution and the pace of payer and prescriber expansion, even as some remain optimistic about the larger AFib-RVR opportunity. These downward revisions have added to the bearish narrative surrounding the shares.
Market Context and Trading Activity
The move occurred against a backdrop of broader risk aversion toward unprofitable micro-cap biotechnology companies. MIST has underperformed the wider market substantially in 2026, and Friday's slide extended a decline that has taken the stock well below its 50-day and 200-day moving averages. Daily trading volume has generally run below the stock's trailing average in recent sessions, suggesting the decline is being driven more by a lack of buyers and persistent selling pressure than by a single large liquidation event. The break below the prior 52-week low marked a notable technical deterioration.
What Comes Next for MIST
Investors now look ahead to third-quarter results, expected around November 11, for fresh data on prescription growth, gross-to-net trends, and any update to the company's cash runway. The ongoing Phase 3 ReVeRA-301 trial of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) remains a key longer-term catalyst, but it will not produce near-term revenue. Key risks include continued slow commercial adoption, additional financing needs, and elevated short interest that could fuel further volatility. Any sustained improvement in CARDAMYST revenue or payer coverage would be closely watched as a potential inflection point.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that track thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to monitor algorithmically generated signals. Explore the page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIST's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for MIST moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 26 of the 30 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 12, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.802) is normal, around the industry mean (2.973). P/E Ratio (-1.081) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement